A Multicenter Randomized Double-Blind Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn s Disease

Brief description of study

The purpose of this study is to assess an investigational drug called etrasimod (also referred to as the “study drug”) in the treatment of Crohn’s disease (CD). “Investigational” means that etrasimod has not been approved by any regulatory authorities, including the US Food and Drug Administration (FDA), therefore, it is not available by prescription.

Clinical Study Identifier: s21-00122
ClinicalTrials.gov Identifier: NCT04173273
Principal Investigator: David P Hudesman.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.